RankAlpha logo
Back to Rankings

AMLX

AmylyxC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The bullish case is that completed LUCIDITY enrollment de-risks execution, prior avexitide studies showed statistically significant hypoglycemia reductions, and the reported cash runway into 2028 gives AMLX enough time to reach its main value-defining readout without obvious immediate financing stress [#8-K-2026-03-24] [#10-K-2026-03-03].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +11.3.
What can break
AMLX remains heavily dependent on a successful Phase 3 avexitide outcome, making the setup binary despite multiple programs.
Momentum
81
Value
41
Sentiment
39
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $17.00 · Bull $24.00 · Bear $9.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $24.40
Why
Momentum81 · Δ7d +11.3
Value41 · Δ7d -0.1
Sentiment39 · Δ7d -2.5
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
81
26% active weight
Current posture
7d trendImproving
Δ7d
+11.3
Δ21d
+19.4
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
39
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.5
Δ21d
-0.9
Why this grade

Composite grade C. Momentum 80.9 / Value 41.1 / Sentiment 39.1

Fundamentals (TTM)
As of 2026-07-20
Market Cap
$1.94B
Beta
-0.30
Shares Out
111.19M
P/E (TTM) · Derived
-11.4
P/S (TTM)
3249.71
P/FCF (TTM) · Derived
-14.57
Rev YoY
-100.0%
EPS YoY
-10.9%
Gross Margin
-94.5%
Op Margin
-47349.8%
Net Debt
-$311.02M
Current Ratio
17.85
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology